Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05358886 · ClinicalTrials.gov registry record · Phase 3
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
A Phase 3 study, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT05358886: Completed Phase 3 study, sponsored by Tetra Discovery Partners.
NCT05358886 is a Phase 3 study that has completed, run by Tetra Discovery Partners. The registered enrollment target is 171 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05358886, a Phase 3 study, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome
Interventions
- DRUG Placebo
- DRUG BPN14770/ zatolmilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2025-07-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05358886
The ClinicalTrials.gov registry entry for NCT05358886 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetra Discovery Partners, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05358886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05358886 about?
NCT05358886 is a clinical study titled "A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome". A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome
What is the current status of trial NCT05358886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2022-11-01. Estimated completion is 2025-07-18.
What interventions are being tested in trial NCT05358886?
The interventions under investigation include: Placebo (DRUG), BPN14770/ zatolmilast (DRUG).
Who is sponsoring clinical trial NCT05358886?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.